Financial News

Point Biopharma Stock Nearly Doubles On Eli Lilly Deal

Eli Lilly is spending $1.4 billion on buying Point Biopharma Global Inc. Point Biopharma is a radiopharmaceutical company focused on cancer treatment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback